• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·ARTEMISMED.NS
Share

Artemis Medicare Services Limited Stocks

₹ 254.75Last Updated 11.06.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

₹ 427.74M

₹ 254.75
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Artemis Medicare Services Limited is engaged in the management and operation of numerous multi-specialty hospitals, extending its healthcare provision across India and internationally. The company offers a comprehensive range of medical and surgical treatments, catering to both admitted patients requiring overnight stays and those seeking outpatient consultations. A key asset within its portfolio is the 541-bed multi-specialty Artemis Hospital, located in Gurugram, India. Founded in 2004, Artemis Medicare Services Limited is headquartered in Gurugram, India.

Company Valuation

Slightly overvalued
3/7

Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBI

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of ARTEMISMED.NS is 339 and suggests 31% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation t

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.06.2026 01:34

Rally ahead of SpaceX debut: best day since April for S&P 500 and Nasdaq, oil down 5%

12.06.2026 01:01

SpaceX holds record IPO: Elon Musk's space company raises $75 billion

12.06.2026 00:55

Google discusses producing part of its new AI chip at Samsung factories. Is this a threat to TSMC?

12.06.2026 00:10

BofA raised its rating on Intel stock by two notches at once. What is the bank betting on?

11.06.2026 22:46

Trump canceled planned new strikes on Iran. Oil below $90 per barrel

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026